Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Merli

Showing results (51-60 of 156) with videos related to

Pageof 16
Sort By:
Cancers|September 28, 2021
EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1)Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, et al.
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Journal of Cachexia, Sarcopenia and Muscle|June 11, 2021
Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experienceVittorio Ruggero Zilioli, Domenico Albano, Annalisa Arcari, et al.
The Lancet. Haematology|May 7, 2017
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trialAndrew Davies, Francesco Merli, Biljana Mihaljević, et al.
Cancer|September 17, 2004
The clinical value of tumor burden at diagnosis in Hodgkin lymphomaPaolo G Gobbi, Chiara Broglia, Giuseppe Di Giulio, et al.
Computer Methods and Programs in Biomedicine|November 4, 2019
Texture analysis and multiple-instance learning for the classification of malignant lymphomasMarco Lippi, Stefania Gianotti, Angelo Fama, et al.
European Journal of Haematology|April 7, 2022
Mixed T cell CHIMERISM in bone marrow at day+30 after allogeneic stem cell transplantation: Correlation with acute GVHD grades III-IV and no impact on relapse and overall survivalSamantha Guidotti, Simona Bassi, Angela Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei LinfomiLuca Baldini, Maura Brugiatelli, Stefano Luminari, et al.
European Journal of Haematology|February 3, 2006
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 studyMassimo Federico, Stefano Luminari, Paolo G Gobbi, et al.
Leukemia & Lymphoma|April 11, 2003
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)Marco Lombardo, Fortunato Morabito, Francesco Merli, et al.
Pageof 16

Showing results (51-60 of 156) with videos related to

Sort By:
Pageof 16
Cancers|September 28, 2021
EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1)Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, et al.
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Journal of Cachexia, Sarcopenia and Muscle|June 11, 2021
Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experienceVittorio Ruggero Zilioli, Domenico Albano, Annalisa Arcari, et al.
The Lancet. Haematology|May 7, 2017
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trialAndrew Davies, Francesco Merli, Biljana Mihaljević, et al.
Cancer|September 17, 2004
The clinical value of tumor burden at diagnosis in Hodgkin lymphomaPaolo G Gobbi, Chiara Broglia, Giuseppe Di Giulio, et al.
Computer Methods and Programs in Biomedicine|November 4, 2019
Texture analysis and multiple-instance learning for the classification of malignant lymphomasMarco Lippi, Stefania Gianotti, Angelo Fama, et al.
European Journal of Haematology|April 7, 2022
Mixed T cell CHIMERISM in bone marrow at day+30 after allogeneic stem cell transplantation: Correlation with acute GVHD grades III-IV and no impact on relapse and overall survivalSamantha Guidotti, Simona Bassi, Angela Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei LinfomiLuca Baldini, Maura Brugiatelli, Stefano Luminari, et al.
European Journal of Haematology|February 3, 2006
The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 studyMassimo Federico, Stefano Luminari, Paolo G Gobbi, et al.
Leukemia & Lymphoma|April 11, 2003
Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL)Marco Lombardo, Fortunato Morabito, Francesco Merli, et al.
Pageof 16